Key points
Sotatercept (Winrevair) is a subcutaneous injection given once every three weeks to adults with pulmonary arterial hypertension (PAH), in addition to background therapy. It is the first drug to act not on spasm but on the growth of the vessel wall; it was approved by the FDA in March 2024.
| Situation | How it helps | What human studies showed |
|---|---|---|
| High-risk PAH, on maximum tolerated background therapy | fewer deaths, lung transplants or hospitalisations for worsening | ZENITH (NEJM, 2025), 172 patients: 17.4% versus 54.7% on placebo, hazard ratio 0.24 (95% CI 0.13–0.43; p<0.001) [2] |
| Hospitalisations (high risk) | fewer hospital admissions for worsening | ZENITH: 9.3% versus 50.0% on placebo [2] |
| PAH on stable background therapy | patients walk further in the six-minute walk test | STELLAR (NEJM, 2023), 323 patients: 40.8 m more than on placebo (95% CI 27.5–54.1; p<0.001); eight of nine secondary endpoints favoured the drug [1] |
How it helps
What happens in the pulmonary vessels
Pulmonary arterial hypertension is not high blood pressure in the familiar sense. It concerns the vessels carrying blood from the heart to the lungs.
Cells in the walls of those arteries begin to multiply excessively. The wall thickens, the lumen narrows, resistance to flow rises. The right ventricle must push blood through ever narrower vessels — and gradually wears out.
Clinically this is breathlessness on exertion, fatigue and fainting. The disease is rare, but untreated the outlook is poor.
How it differs from earlier drugs
The three classes on which treatment rested for decades — prostacyclins, endothelin receptor antagonists and phosphodiesterase-5 inhibitors — all essentially do one thing: widen the vessel by relieving spasm.
This works and prolongs life. But the wall keeps thickening regardless of whether the vessel is widened. Figuratively: the pipe furs up from inside while we adjust its bore from outside.
How the trap works
Two opposing signals meet in the cells of the vessel wall:
| Signal | What it does | What happens in the disease |
|---|---|---|
| Through the BMPR2 receptor | Restrains cell division | Weakened |
| Through activins and related proteins | Drives division | Amplified |
The balance tips toward growth, and the wall thickens. This is precisely why mutations in the BMPR2 gene are found in a substantial share of patients with the hereditary form.
Sotatercept is built as a fragment of the receptor fused to part of an antibody. It works as a trap: it captures surplus activins from the blood before they reach the cells. The advantage returns to the restraining signal.
Trials
▸ ZENITH (NEJM, 2025) — 172 high-risk patients on the maximum tolerated background therapy. Events were counted rather than metres [2]:
| Event | Sotatercept | Placebo |
|---|---|---|
| Composite (death, lung transplantation or hospitalisation) | 17.4% | 54.7% |
| Death from any cause | 8.1% | 15.1% |
| Lung transplantation | 1.2% | 7.0% |
| Hospitalisation for worsening | 9.3% | 50.0% |
The trial was stopped early. The interim analysis showed an advantage so clear that continuing to give placebo became unethical.
How it is given
| Parameter | Detail |
|---|---|
| Route | Subcutaneous injection |
| Frequency | Once every three weeks |
| Role in the regimen | Added to background therapy |
| Monitoring | Haemoglobin and platelets before every dose during titration |
| Discuss in advance | Fertility |
Who should see a doctor first
Side effects
▸ Nosebleeds and telangiectasia — dilated small vessels on the skin and mucous membranes; the most characteristic events.
▸ Rising haemoglobin: the blood thickens more than it should, so levels are monitored regularly.
▸ Falling platelets — the same blood counts cover this.
▸ Effects on fertility: drugs of this class may affect reproductive function, and that conversation belongs before treatment rather than after.
Who it is not for
▸ Patients with pulmonary hypertension of another origin — the mechanism does not address them.
▸ Anyone with an already high haemoglobin or low platelets — decided case by case and requiring monitoring.
▸ Anyone planning pregnancy without discussing the fertility question with their doctor.
▸ As a reason to stop background therapy that is working.
Bottom line
▸ The first mechanism aimed at growth of the vessel wall rather than spasm.
▸ ZENITH: events in 17.4% versus 54.7%; the trial was stopped early for efficacy.
▸ Under regular monitoring — nosebleeds, telangiectasia, rising haemoglobin and falling platelets.
Treatment can be discussed at a consultation; the drug can be ordered here.
References
1. Hoeper MM, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478–1490. PMID 36877098
2. Humbert M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025;392(20):1987–2000. PMID 40167274
3. WINREVAIR (sotatercept-csrk) — US Prescribing Information, Merck.
Source: Sotatercept (Winrevair): The First Drug in Pulmonary Hypertension That Treats the Narrowing, Not the Spasm — universum.earth. Dr. Pereligyn.
